Sustained Analgesia Achieved Through Esterase-Activated Morphine Prodrugs Complexed with PAMAM Dendrimer
- 28 September 2012
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 30 (1) , 247-256
Abstract
Design and evaluate the in vitro and in vivo efficacy of two extended release morphine formulations developed for IV administration by complexing esterase activated morphine prodrugs to surface-modified, generation 5 (G5) poly(amidoamine) (PAMAM) dendrimer.Keywords
This publication has 35 references indexed in Scilit:
- Plasma-mediated release of morphine from synthesized prodrugsBioorganic & Medicinal Chemistry Letters, 2010
- Synthesis, characterization, and intracellular uptake of carboxyl-terminated poly(amidoamine) dendrimer-stabilized iron oxide nanoparticlesPhysical Chemistry Chemical Physics, 2007
- HER2 Specific Tumor Targeting with Dendrimer Conjugated Anti-HER2 mAbBioconjugate Chemistry, 2006
- Targeted drug delivery with dendrimers: Comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complexAdvanced Drug Delivery Reviews, 2005
- HPLC analysis of PAMAM dendrimer based multifunctional devicesJournal of Chromatography B, 2005
- Generational, skeletal and substitutional diversities in generation one poly(amidoamine) dendrimersPolymer, 2005
- Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymersInternational Journal of Pharmaceutics, 2003
- Improvement of buccal delivery of morphine using the prodrug approachInternational Journal of Pharmaceutics, 1997
- Bioactivation of morphine-3-propionate, a prodrug of morphine, in tissues from different speciesInternational Journal of Pharmaceutics, 1997
- Hydrolysis of copolyesters containing aromatic and aliphatic ester blocks by lipaseJournal of Applied Polymer Science, 1981